

Diabetic Retinopathy Guideline Committee Meeting 11

Date: 19th April 2023
Location: Virtual Meeting via Zoom
Minutes: Final

Committee members present:	
Mike Burdon (MB – Chair)	Present for all items
Amandeep Bedi	Present for all items
Philip Burgess	Present for all items
Rosalind Creer	Present for all items
Julie Davey	Present for all items
Christiana Dinah	Present for all items
Noemi Lois	Present for all items
Louis Savage	Present for all items
Diva Shah	Present for all items
Lloyd Thomas	Present for all items
Becky Wei Luo	Present for all items

In attendance:		
Astrid Aregui (AA)	Senior Medical Editor, NICE	Present for all items
Keona Bennett	Administrator, Guideline Development Team	Present for item 1
Catrina Charlton	Guideline Commissioning Manager, NICE	Present for all items
Clare Dadswell (CD)	Senior Technical Analyst	Present for all items
Jon Littler (JL)	Project Manager, Guideline Development Team	Present for all items
Kirsty Luckham (KL)	Technical Analyst (Health Economics)	Present for all items
Syed Mohiuddin	Technical Adviser (Health Economics)	Present for all items
Hannah Tebbs	Technical Analyst (Health Economics)	Present for all items
Philip Williams	NICE Resource Impact Lead	Present for all items
Ahmed Yosef (AY)	Technical Analyst, Guideline Development Team	Present for all items

Apologies:	
John Anderson	Committee Member
Bernadette Warren	Committee Member

1. Welcome and DOIs for the meeting

The Chair welcomed the committee members and attendees to the 11th meeting on Diabetic Retinopathy. The committee members and attendees introduced themselves. The Chair informed the Committee that apologies had been received, these are noted above.

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was Diabetic Retinopathy. The Chair asked everyone to verbally declare any new interests that are not listed in the registry. No new interests were declared, but it was decided that Noemi Lois, who worked on the EMERALD study, could be part of the first item of discussion but would not be involved in making any recommendations in session 3.

Finally, the minutes from committee 10 were reviewed and agreed as an accurate record of the discussions held at that meeting.

2. Review question 12 – *What is the diagnostic test accuracy of ultra-wide field imaging and optical coherence tomography for monitoring?*

The Chair, Mike Burdon (MB) introduced Ahmed Yosef (AY), Technical Analyst, who presented a review of the clinical evidence for review question 12. After completing his presentation, AY took questions from the committee on the sources of the data and how it was reviewed, and how it may subsequently be interpreted into recommendations.

Once the discussion concluded, the Chair thanked AY for his presentation and moved on to the next item on the agenda.

3. Review question 12 – *What is the diagnostic test accuracy of ultra-wide field imaging and optical coherence tomography for monitoring?*

- Making recommendations

The Chair introduced Clare Dadswell (CD), Senior Technical Analyst. Having had the clinical evidence presented to them by AY, CD now presented the committee with possible recommendations that could be drawn from that evidence. The committee discussed these possible recommendations, making additions and changes where required.

The Chair then thanked CD for her work, and the committee for their contribution, before breaking for lunch and the subsequent afternoon agenda items.

4. Review question 2 – *What is the effectiveness of different thresholds or criteria for starting treatment for non-proliferative diabetic retinopathy, proliferative diabetic retinopathy, and diabetic macular oedema?*

The Chair reintroduced CD in order to revisit the clinical evidence and early draft recommendations review question 2.

After taking questions on how the evidence had been used to draft the recommendations and showing the committee how their early suggestions on recommendations had been incorporated, they were asked to contribute final changes to the versions that would be submitted for consultation.

MB thanked CD, the team and the committee for their work in developing the recommendations for this review question and moved to the final main item on the agenda.

5. Review question 7 – *What is the effectiveness and acceptability of intravitreal steroids, laser*

photocoagulation and anti-vascular endothelial growth factor agents for treating diabetic macular oedema?

The Chair reintroduced CD along with Kirsty Luckham (KL), Health Economic Analyst, in order to revisit the clinical evidence for review question 7 and guide the committee through the updated results from KL's economic modelling.

After taking questions from the committee on the clinical evidence, KL presented her updated economic evidence to the committee and took additional questions.

MB thanked KL and CD for their work, the committee for their input, and moved to the AOB section of the agenda.

6. AOB, summary and next steps

The Chair thanked those present for their contributions and reminded all attendees that the following committee was the next day (Thursday 20th April) before concluding this meeting.